↓ Skip to main content

Recent advances in migraine therapy

Overview of attention for article published in SpringerPlus, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter
8 tweeters
facebook
1 Facebook page
wikipedia
5 Wikipedia pages
googleplus
1 Google+ user

Citations

dimensions_citation
99 Dimensions

Readers on

mendeley
240 Mendeley
Title
Recent advances in migraine therapy
Published in
SpringerPlus, May 2016
DOI 10.1186/s40064-016-2211-8
Pubmed ID
Authors

Fabio Antonaci, Natascia Ghiotto, Shizheng Wu, Ennio Pucci, Alfredo Costa

Abstract

Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the condition must be carefully explained to the patient soon as it is diagnosed. The range of available acute treatments has increased over time. At present, abortive migraine therapy can be classed as specific (ergot derivatives and triptans) or non-specific (analgesics and non-steroidal anti-inflammatory drugs). Even though acute symptomatic therapy can be optimised, migraine continues to be a chronic and potentially progressive condition. In addition to the drugs officially approved for migraine prevention by international governmental regulatory agencies, numerous different agents are commonly used for this indication, showing various levels of evidence of efficacy and tolerability. Guidelines published in recent years, based on evidence-based medicine data on migraine prophylaxis, are a useful source of guidance, especially for primary care physicians and neurologists without specific expertise in headache medicine. Although the field of pharmacological migraine prevention has seen few advances in recent years, potential novel approaches are now being developed. This review looks at emerging pharmacological strategies for acute and preventive migraine treatment that are nearing or have already entered the clinical trial phase. Specifically, it discusses preclinical and clinical data on compounds acting on calcitonin gene-related peptide or its receptor, the serotonin 5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channel blockers.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 240 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Peru 1 <1%
Brazil 1 <1%
Unknown 237 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 35 15%
Other 32 13%
Student > Master 32 13%
Researcher 22 9%
Student > Ph. D. Student 20 8%
Other 46 19%
Unknown 53 22%
Readers by discipline Count As %
Medicine and Dentistry 62 26%
Pharmacology, Toxicology and Pharmaceutical Science 39 16%
Neuroscience 20 8%
Biochemistry, Genetics and Molecular Biology 16 7%
Nursing and Health Professions 12 5%
Other 29 12%
Unknown 62 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#3,092,463
of 22,747,498 outputs
Outputs from SpringerPlus
#183
of 1,853 outputs
Outputs of similar age
#55,388
of 326,586 outputs
Outputs of similar age from SpringerPlus
#17
of 192 outputs
Altmetric has tracked 22,747,498 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,853 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,586 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.